S&P 500   4,335.53 (+0.36%)
DOW   33,999.63 (+0.11%)
QQQ   358.73 (+0.23%)
AAPL   175.55 (+0.43%)
MSFT   316.77 (-0.08%)
META   300.10 (+0.34%)
GOOGL   130.88 (+0.48%)
AMZN   131.00 (+1.46%)
TSLA   245.90 (+0.42%)
NVDA   419.22 (+0.75%)
NIO   8.35 (-2.11%)
BABA   86.98 (-1.49%)
AMD   97.09 (+0.93%)
T   15.07 (-0.33%)
F   12.56 (+1.05%)
MU   68.43 (-0.65%)
CGC   0.93 (+10.73%)
GE   111.58 (+0.30%)
DIS   81.03 (-0.27%)
AMC   8.17 (+7.22%)
PFE   32.91 (+0.67%)
PYPL   58.72 (+1.45%)
NFLX   384.26 (+1.17%)
S&P 500   4,335.53 (+0.36%)
DOW   33,999.63 (+0.11%)
QQQ   358.73 (+0.23%)
AAPL   175.55 (+0.43%)
MSFT   316.77 (-0.08%)
META   300.10 (+0.34%)
GOOGL   130.88 (+0.48%)
AMZN   131.00 (+1.46%)
TSLA   245.90 (+0.42%)
NVDA   419.22 (+0.75%)
NIO   8.35 (-2.11%)
BABA   86.98 (-1.49%)
AMD   97.09 (+0.93%)
T   15.07 (-0.33%)
F   12.56 (+1.05%)
MU   68.43 (-0.65%)
CGC   0.93 (+10.73%)
GE   111.58 (+0.30%)
DIS   81.03 (-0.27%)
AMC   8.17 (+7.22%)
PFE   32.91 (+0.67%)
PYPL   58.72 (+1.45%)
NFLX   384.26 (+1.17%)
S&P 500   4,335.53 (+0.36%)
DOW   33,999.63 (+0.11%)
QQQ   358.73 (+0.23%)
AAPL   175.55 (+0.43%)
MSFT   316.77 (-0.08%)
META   300.10 (+0.34%)
GOOGL   130.88 (+0.48%)
AMZN   131.00 (+1.46%)
TSLA   245.90 (+0.42%)
NVDA   419.22 (+0.75%)
NIO   8.35 (-2.11%)
BABA   86.98 (-1.49%)
AMD   97.09 (+0.93%)
T   15.07 (-0.33%)
F   12.56 (+1.05%)
MU   68.43 (-0.65%)
CGC   0.93 (+10.73%)
GE   111.58 (+0.30%)
DIS   81.03 (-0.27%)
AMC   8.17 (+7.22%)
PFE   32.91 (+0.67%)
PYPL   58.72 (+1.45%)
NFLX   384.26 (+1.17%)
S&P 500   4,335.53 (+0.36%)
DOW   33,999.63 (+0.11%)
QQQ   358.73 (+0.23%)
AAPL   175.55 (+0.43%)
MSFT   316.77 (-0.08%)
META   300.10 (+0.34%)
GOOGL   130.88 (+0.48%)
AMZN   131.00 (+1.46%)
TSLA   245.90 (+0.42%)
NVDA   419.22 (+0.75%)
NIO   8.35 (-2.11%)
BABA   86.98 (-1.49%)
AMD   97.09 (+0.93%)
T   15.07 (-0.33%)
F   12.56 (+1.05%)
MU   68.43 (-0.65%)
CGC   0.93 (+10.73%)
GE   111.58 (+0.30%)
DIS   81.03 (-0.27%)
AMC   8.17 (+7.22%)
PFE   32.91 (+0.67%)
PYPL   58.72 (+1.45%)
NFLX   384.26 (+1.17%)
NASDAQ:IRWD

Ironwood Pharmaceuticals (IRWD) Stock Forecast, Price & News

$9.48
+0.19 (+2.05%)
(As of 03:46 PM ET)
Compare
Today's Range
$8.98
$9.51
50-Day Range
$8.25
$11.35
52-Week Range
$8.07
$12.66
Volume
1.65 million shs
Average Volume
2.32 million shs
Market Capitalization
$1.48 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

Ironwood Pharmaceuticals MarketRank™ Forecast

Analyst Rating
0.00 Rating Score
Upside/​Downside
100.6% Upside
$19.00 Price Target
Short Interest
Bearish
10.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.94
Upright™ Environmental Score
News Sentiment
0.81mentions of Ironwood Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$300,119 Bought Last Quarter
Proj. Earnings Growth
-50.78%
From $1.28 to $0.63 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

Medical Sector

834th out of 961 stocks

Pharmaceutical Preparations Industry

402nd out of 456 stocks


IRWD stock logo

About Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

IRWD Price History

IRWD Stock News Headlines

Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 2.1%
Top Wellness Nasdaq Stock for 2023
Cutting-Edge Ai-Based Technology Is Set to Disrupt the Womens Wellness Space
Implied Volatility Surging for Ironwood (IRWD) Stock Options
The Next Best AI Stock to Watch After Nvidia
This emerging NASDAQ company may be the best AI stock to watch in the AI boom.
Earnings Preview For Ironwood Pharmaceuticals
Ironwood Scoops Up Gastrointestinal Diseases Player For $1B
Why VectivBio Shares Are Surging Monday
See More Headlines
Receive IRWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IRWD Company Calendar

Last Earnings
8/08/2023
Today
9/25/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IRWD
CUSIP
46333X10
Employees
219
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+103.4%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$175.07 million
Net Margins
-214.68%
Pretax Margin
-203.19%

Debt

Sales & Book Value

Annual Sales
$410.60 million
Cash Flow
$1.15 per share
Book Value
$4.24 per share

Miscellaneous

Free Float
135,589,000
Market Cap
$1.46 billion
Optionable
Optionable
Beta
0.96
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Ms. Julie H. McHughMs. Julie H. McHugh (Age 59)
    Exec. Chairman
    Comp: $95k
  • Mr. Thomas A. McCourtMr. Thomas A. McCourt (Age 66)
    CEO & Director
    Comp: $1.42M
  • Mr. Sravan Kumar Emany (Age 45)
    Sr. VP, Principal Financial Officer & CFO
    Comp: $712.36k
  • Mr. John Minardo (Age 47)
    Sr. VP, Chief Legal Officer & Sec.
    Comp: $675.88k
  • Dr. Michael Shetzline M.D. (Age 64)
    Ph.D., Chief Medical Officer, Sr. VP and Head of Research & Drug Devel.
    Comp: $837.74k
  • Mr. Ronald SilverMr. Ronald Silver (Age 41)
    Corp. Controller & Principal Accounting Officer
  • Mr. Marcel Moulaison
    VP of Technical Operations
  • Greg Martini
    VP of Strategic Fin. & Investor Relations
  • Ms. Beth Calitri
    Head of Corp. Communications & Media Relations
  • Mr. Mike Nanfito
    VP of Sales & Sales Excellence













IRWD Stock - Frequently Asked Questions

What is Ironwood Pharmaceuticals' stock price forecast for 2023?

0 Wall Street analysts have issued 1 year price objectives for Ironwood Pharmaceuticals' stock. Their IRWD share price forecasts range from $19.00 to $19.00. On average, they predict the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 103.4% from the stock's current price.
View analysts price targets for IRWD
or view top-rated stocks among Wall Street analysts.

How have IRWD shares performed in 2023?

Ironwood Pharmaceuticals' stock was trading at $12.39 at the start of the year. Since then, IRWD stock has decreased by 24.6% and is now trading at $9.34.
View the best growth stocks for 2023 here
.

When is Ironwood Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our IRWD earnings forecast
.

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) released its quarterly earnings results on Tuesday, August, 8th. The biotechnology company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.25 by $0.06. The biotechnology company had revenue of $107.38 million for the quarter, compared to the consensus estimate of $103.46 million. Ironwood Pharmaceuticals had a negative net margin of 214.68% and a positive trailing twelve-month return on equity of 55.17%.

What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?

Ironwood Pharmaceuticals issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $435.00 million-$450.00 million, compared to the consensus revenue estimate of $427.88 million.

What is Mark Mallon's approval rating as Ironwood Pharmaceuticals' CEO?

7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among the company's employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ironwood Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX).

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Who are Ironwood Pharmaceuticals' major shareholders?

Ironwood Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.61%), State Street Corp (7.10%), LSV Asset Management (4.94%), Dimensional Fund Advisors LP (3.61%), Renaissance Technologies LLC (3.42%) and Brown Capital Management LLC (2.41%). Insiders that own company stock include Alexander J Denner, Andrew Davis, Jason Rickard, Julie Mchugh, Kelly Macdonald, Mark G Currie, Marla L Kessler, Michael Shetzline, Ronald Silver, Sravan Kumar Emany, Thomas A Mccourt and Timothy M O'reilly.
View institutional ownership trends
.

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ironwood Pharmaceuticals' stock price today?

One share of IRWD stock can currently be purchased for approximately $9.34.

How much money does Ironwood Pharmaceuticals make?

Ironwood Pharmaceuticals (NASDAQ:IRWD) has a market capitalization of $1.46 billion and generates $410.60 million in revenue each year. The biotechnology company earns $175.07 million in net income (profit) each year or ($6.04) on an earnings per share basis.

How many employees does Ironwood Pharmaceuticals have?

The company employs 219 workers across the globe.

How can I contact Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The official website for the company is www.ironwoodpharma.com. The biotechnology company can be reached via phone at (617) 621-7722, via email at mkaya@ironwoodpharma.com, or via fax at 617-494-0480.

This page (NASDAQ:IRWD) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -